BOTHELL, WA--(Marketwired - August 15, 2014) - Cocrystal Pharma, Inc. (the "Company") (OTCBB: COCP) (OTCQB: COCP), a biotechnology company developing new antiviral therapeutics for human diseases, today reported financial results for the second quarter ended June 30, 2014.
Select financial and operational highlights include:
Select program highlights from the quarter include:
CEO Dr. Gary Wilcox stated, "We are pleased to report that we continue to move our drug candidates closer towards clinical development. By employing unique technologies and Nobel Prize winning expertise to drug discovery, we believe we have established a technology pipeline designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. We look forward to sharing future milestones with our stakeholders as they develop."
To learn more about the company go to our webpage at www.cocrystalpharma.com.
About Cocrystal Pharma, Inc.
Cocrystal is a biopharma company that seeks to develop novel technologies and approaches to create first-in-class and best-in-class broad-spectrum antiviral therapeutics for the treatment and prophylaxis of viral diseases in humans.
Cautionary Statement Regarding Forward-Looking Statements:
This press release contains forward-looking statements including those relating to the timing of initiation of clinical trials and filing an IND. Forward-looking statements also are prefaced by words such as "expect," "plan," "intend," "anticipate," and similar words. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements for a variety of reasons including delays in reviewing laboratory test results and those contained in our Form 10-K, as amended, for the year ended December 31, 2013. We caution you therefore against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. We do not undertake any duty to update these forward-looking statements.